ClinicalTrials.gg

Program

GR2301

A development code. Also written as “GR2301 injection”.

Its studies are mostly in Vitiligo, led by Chongqing Genrix Biopharmaceutical.

Furthest: phase 2, since May 25, 20264 company-led studies, 4 open or runningNext primary completion: Jul 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Genrix Biopharmaceutical44 open or runningphase 2since May 25, 2026Sep 17, 2025Jul 2027phase 1 · NCT07647224

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 17, 2025First study: phase 1 study in Single Ascending DoseFirst studyNCT07190716 · 36 planned · China
  2. May 24, 2026Phase 1 study in Multiple DoseNCT07647224 · 36 planned · China
  3. May 25, 2026Phase 2 study in VitiligoPhase 2 reachedNCT07647237 · 116 planned
  4. Nov 5, 2026Phase 2 study in VitiligoNCT07930039 · 120 planned

Ahead

  1. Jul 2027Primary completion: phase 1 study in Multiple DoseNCT07647224
  2. May 2028Primary completion: phase 2 study in VitiligoNCT07930039
  3. Jun 2028Primary completion: phase 2 study in VitiligoNCT07647237

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07930039Vitiligo2Not yet recruitingMay 2028120
NCT07647237Vitiligo2Not yet recruitingJun 2028116
NCT07647224Multiple Dose · China1Not yet recruitingJul 202736
NCT07190716Single Ascending Dose · China1Not yet recruitingMay 30, 202636

How it is read

Names in the registry

  • “GR2301 injection”, 4 entries

Codes read as this program: GR2301.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.